(Q44176007)

30 November 2017

Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer (English)

1 reference

30 November 2017

1 reference

I H Park

1

1 reference

30 November 2017

J Ro

2

1 reference

30 November 2017

K S Lee

3

1 reference

30 November 2017

B H Nam

4

1 reference

30 November 2017

Y Kwon

5

1 reference

30 November 2017

K H Shin

6

1 reference

30 November 2017

29 July 2008

1 reference

30 November 2017

1 reference

30 November 2017

20

1 reference

30 November 2017

1

1 reference

30 November 2017

56-62

1 reference

CNS metastases in breast cancer

30 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN539

Breast cancer subtypes and survival in patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN539

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN539

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN539

Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN539

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN539

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN539

Survival after brain metastases from breast cancer in the trastuzumab era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN539

Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN539

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN539

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN539

Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN539

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDN539

1 reference

30 November 2017

1 reference